Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.

Nat Rev Rheumatol 2019 Aug 10;15(8):461-474. Epub 2019 Jul 10.

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

Cardiometabolic comorbidities present a considerable burden for patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA). Both RA and PsA are associated with an increased risk of cardiovascular disease (CVD). PsA more often exhibits an increased risk of metabolically linked comorbidities such as obesity, insulin resistance, type 2 diabetes mellitus and non-alcoholic fatty liver disease. Although both RA and PsA are characterized by a state of chronic inflammation, the mechanisms that contribute to CVD risk in these conditions might not be identical. In RA, systemic inflammation is thought to directly contribute to CVD risk, whereas in PsA, adiposity is thought to contribute to a notable metabolic phenotype that, in turn, contributes to CVD risk. Hence, appropriate management strategies that consider the increased risk of cardiometabolic comorbidities in patients with inflammatory arthropathy are important. In RA, such strategies should focus on the prediction of CVD risk and its management through targeting chronic inflammation and traditional CVD risk factors. In PsA, management strategies should additionally focus on targeting metabolic components, including weight management, which might not only help improve disease activity in the joints, entheses and skin, but also reduce the risk of metabolic comorbidities and improve the quality of life of patients.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0256-0DOI Listing
August 2019
2 Reads

Publication Analysis

Top Keywords

cvd risk
20
increased risk
12
cardiometabolic comorbidities
12
risk
9
management strategies
8
contribute cvd
8
psa
7
cvd
6
management
4
risk appropriate
4
appropriate management
4
phenotype turn
4
turn contributes
4
contributes cvd
4
comorbidities patients
4
inflammatory arthropathy
4
arthropathy strategies
4
patients inflammatory
4
metabolic phenotype
4
consider increased
4

References

(Supplied by CrossRef)

A Ogdie et al.
Ann. Rheum. Dis. 2014

A Jamnitski et al.
Ann. Rheum. Dis. 2013

M Mahmoudi et al.
Int. J. Rheum. Dis. 2017

A Budu-Aggrey et al.
PLOS Med. 2019

MND Minno Di et al.
Ann. Rheum. Dis. 2014

E Klingberg et al.
Arthritis Res. Ther. 2019

K Jafri et al.
Arthritis Care Res. 2017

A Hot et al.
Ann. Rheum. Dis. 2012

N Sattar et al.
Circulation 2003

JA Avina-Zubieta et al.
Ann. Rheum. Dis. 2012

O Schieir et al.
Ann. Rheum. Dis. 2017

Similar Publications